Vaccine news a setback for Sanofi and its revenue picture

With some of its best-selling drugs falling off the patient cliff, and big employee cuts looming in France, Sanofi ($SNY) is looking for improved sales elsewhere--like from its vaccine division. One of its most promising vaccines, with sales estimated to push beyond $1 billion, is a treatment for four strains of the deadly dengue fever. But it got the chair knocked out from under it on that one this week when it reported the vaccine failed to protect against a strain common in Thailand. Success with the study could have set Sanofi up for regulatory approval but now it must wait for results of two trials in Asia and Latin America. Story | More

Suggested Articles

Johnson & Johnson faces a litany of problems, but executives are clearly not concerned—at least not about the company's short-term fortunes.

This week, Goldman Sachs resurrected a burning question: How can pharma companies profit from curing patients with one-time gene and cell therapies?

CMS has determined how it'll pay for Gilead's CAR-T cancer therapy, Yescarta, for outpatient use, but hasn't yet decided on Gilead's…